Company’s BGS Is Most Advanced Device in Category
in More than Two Decades
Jacksonville, FL, April 28, 2026 /OrthoSpineNews/ – Theragen, a Jacksonville, Florida–based medical device company, today announced the issuance of its first European patent (EP 4 288 138 B1), marking a major milestone in the company’s intellectual property strategy. The patent recognizes Theragen’s innovation in spinal fusion bone growth stimulation, positioning the company as having developed the most advanced device in this category in more than two decades.
The patented product, ActaStim®‑S, integrates a clinically proven therapeutic electrical signal with a modern, easy‑to‑wear design and a first‑of‑its‑kind, data‑rich digital health platform. Its small form factor supports continuous, comfortable, and discreet wear in real‑world patient settings, enabling longer daily usage and increasing the likelihood of spinal fusion success.
“This patent award reflects the acknowledgement that Theragen has created a modern and unique device that achieves increased fusion success, enables continuous wear compliance, and has the ability to capture and share important patient healing metrics,” stated Richard Pearce, COO, VP of R&D, and co-inventor. “No other spinal bone growth stimulator can provide these patient and healthcare team benefits.”
ActaStim®‑S includes digital capabilities that measure daily wear time, capture patient activity and pain‑related activities, and track patient‑reported pain. These metrics are available to the patient through the companion Sync App, which displays recovery data via charts and graphs providing a clear view of healing progress and trends. While healthcare professionals also receive patient
recovery insight reporting continuous, real-time, patient specific feedback allowing for timely interventions and adjustments.
“Receiving our first OUS patent is a significant milestone for Theragen. It is validation that our patient-centric approach to design of our products and services resonates in a way never seen before in this category. We are honored to serve an increasing number of patients and their healthcare teams every day,” added Chris McAuliffe, CEO, and co-inventor.
About Theragen
Theragen, Inc. is a leader in the development and manufacture of non-invasive, electrical stimulation DME products that deliver therapeutic energy to improve fusion success and empower patients to play an active role in their recovery. The company is committed to continuous innovation and expanding our reach to help improve outcomes for more patients. To learn more, please visit actastim.com.
About ActaStim®-S
ActaStim®-S uses safe, effective, FDA-approved stimulation technology that’s been prescribed clinically for over 20 years to improve spinal fusion success and help patients get back to the activities they enjoy.1
Source: Theragen
References
1. U.S. Food and Drug Administration. (2020). PMA P190030: FDA Summary of Safety and Effectiveness Data.
